Prognostic value of C-reactive protein-to-albumin ratio and inflammatory markers in esophageal cancer patients treated with chemoradiotherapy

Berrin Inanc 1 * , Ozlem Mermut 1
More Detail
1 Department of Radiation Oncology, Istanbul Training and Research Hospital, Istanbul, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 18, Issue 2, pp. 61-65.
Download Full Text (PDF)


Background: This retrospective research, it was aimed to evaluate disease-free survival (DFS)  using inflammatory markers in esophageal cancer patients who received chemoradiotherapy (CRT).
Methods: A total of 67 patients who received standard curative chemoradiotherapy for esophageal cancer were included in the study between 2011-2018. The patient, treatment characteristics, and pretreatment inflammatory markers were obtained from the patient's file.
Results : Median follow up time was 18 months (6-72 months). ROC curve analyses showed the C-Reactive Protein-to-Albumin (CAR) cut-off  value  0.9 for  DFS (AUC:78.8%; sensitivity: 85%; specificity; 67.5%). 2-year disease free survival for CAR ≥0.9 and CAR  <0.9 were 45.7% and 78%, respectively ( P=0.035). The radiation doses >50Gy (versus <50Gy, p=0.027) and  CAR ratio < 0.9 (versus ≥ 0.9, p=0.005)  appeared significant  associates of better  DFS in univariate  analyses, but the age, gender, stage, localization, neutrophil-to-lympocyte ratio (NLR) and platelet-to-lymhocyte ratio (PLR) were no statistically significant (p>0.005).On the multivariate logistic analysis, our results  showed that CAR < 0.9 [hazard ratio (HR) 1.29; 95% confidence interval [CI], 1.336-2.946; P = 0.014];  and radiation dose >50 Gy (HR 0.91; 95% CI, 1.229-4.997; P = 0.027) independent prognostic indictors.
Conclusion: Our study found that the C-Reactive Protein/Albumin ratio is easy to apply and maybe a promising marker to predict disease-free survival in esophageal cancer patients who received chemoradiotherapy.


Inanc B, Mermut O. Prognostic value of C-reactive protein-to-albumin ratio and inflammatory markers in esophageal cancer patients treated with chemoradiotherapy. J CLIN MED KAZ. 2021;18(2):61-5.


  • World Health Organization. International Agency for Research on Cancer. GLOBOCAN 2018: oesophagus cancer fact sheet. 2018 doi:10.3322/caac.21492
  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. A Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262
  • Amin MB, Edge SB, Greene FL. AJCC cancer staging manual (ed 8). New York, NY: Springer; 2017.
  • Cao J, Yuan P, Wang Li, Wang Y, Ma H, Yuan X, et al. Clinical Nomogram for Predicting Survival of Esophageal Cancer Patients after Esophagectomy. Sci Rep. 2016;6:26684. doi:10.1038/srep26684.
  • Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–e180. doi:10.1016/S1470-2045(14)71116-7
  • Graesslin O, Abdulkarim B, Coutant C, Hguet F, Gabos Z, Hsu L, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 2010; 28:2032–2037. doi:10.1200/JCO.2009.24.6314.
  • Han DS, Suh YS, Kong SH, Lee HJ, Choi Y, Aikou S, et al.Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012 Nov 1;30(31):3834-40. doi: 10.1200/JCO.2012.41.8343.
  • Wan G, Gao F, Chen J, Li Y, Geng M, Sun L, et al.Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma. BMC Cancer. 2017 Jan 31;17(1):91. doi: 10.1186/s12885-017-3062-6.
  • US Department of Health and Human Services. Common Terminology Criteria for Adverse Events(CTCAE); June 14, 2010. Date last updated. Available from:
  • Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357: 539–545. doi:10.1016/S0140-6736(00)04046-0
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013
  • Mantovani A, Allavena P, Sica A, Balkwill F.Cancer-related inflammation. Nature. 2008;454(7203):436-444. doi: 10.1038/nature07205.
  • Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al.“A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy,” Cancer, 2016;122(14):2158–2167. doi: 10.1002/cncr.30057
  • Chen Z, Wang K, Lu H, Xue D, Fan M, Zhuang Q et al.“Systemic inflammation response index predicts prognosis in patients with clear cell renal cell carcinoma: a propensity score-matched analysis,” Cancer Management and Research, 2019; 11:909–919. doi: 10.2147/CMAR.S186976
  • Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y,et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8(4):339–345. doi:10.1016/j.tranon.2015.06.006
  • Tao CJ, Chen YY, Jiang F, Feng XL, Jin QF, Jin T, et al. The C-reactive protein/albumin ratio is an independent prognostic factor for overall survival in patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy. J Cancer. 2016;7(14):2005–2011. doi:10.7150/jca.16210
  • Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komak R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167-1174. doi: 10.1200/JCO.2002.20.5.1167.
  • Shao Y, Ning Z, Chen J, Gang Y, Gu W, Huang J,et al. Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy. Sci Rep. 2015;5:18811. doi:10.1038/srep18811
  • Feng JF, Huang Y, Chen QX. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. World J Surg Oncol. 2014;12:58. doi:10.1186/1477-7819-12-58
  • Liu JS, Huang Y, Yang X, Feng JR. A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma. Am J Cancer Res. 2015;5(7):2180–2189.
  • Ishibashi Y, Tsujimoto H, Yaguchi Y, Kishi Y,Ueno H. Prognostic significance of systemic inflammatory markers in esophageal cancer: Systematic review and meta-analysis. Ann Gastroenterol Surg. 2019;4(1):56-63. doi:10.1002/ags3.12294